Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
Guillermo Garcia-Manero, Pierre Fenaux, Aref Al-Kali, Maria R. Baer, Mikkael A. Sekeres, Gail J. Roboz, Gianluca Gaidano, Bart L. Scott, Peter Greenberg, Uwe Platzbecker, David P. Steensma, Suman Kambhampati, Karl Anton Kreuzer, Lucy A. Godley, Ehab Atallah, Robert Collins, Hagop Kantarjian, Elias Jabbour, Francois E. Wilhelm, Nozar AzarniaLewis R. Silverman
Dive into the research topics of 'Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.